Speaker 1: Bloomberg Audio Studios, podcasts, radio news, The Stock Movers Report,
Speaker 1: your roundup of companies making moves in the stock market,
Speaker 1: harnessing the power of Bloomberg data. Let just take a
Speaker 1: look at some of the stocks on the move today.
Speaker 2: We can do that with bloom Merchant, Natania, Kney, Javich, Natalia.
Speaker 2: What are you looking at today? Let's start with li Lily.
Speaker 2: The ticket is l l y. Shares are flat actually
Speaker 2: right now, but there's a big announcement. So li Lilly
Speaker 2: agreed to buy Kilonia Therapeutics for about seven billion dollars.
Speaker 2: As a result, it can get access to cutting edge
Speaker 2: treatment for blood cancer. So Kilonia's main drug aims to
Speaker 2: treat patients who have a form of blood cancer called
Speaker 2: multiple myeloma. Now the company is enrolling patients in early
Speaker 2: stage of this trial of this of this drug. So
Speaker 2: we know that Ali Lily is mostly famous for weight
Speaker 2: loss drugs, but it is a big player in cancer
Speaker 2: space as well, after it bought a company called Loxa
Speaker 2: Oncology for about eight billion dollars in twenty nineteen. But
Speaker 2: I have to point out shares are still no Actually,
Speaker 2: it is a pretty good performance. So if you look
Speaker 2: at a twelve month basis up fourteen percent, but on
Speaker 2: a year to date there are some losses. Yep, all right,
Speaker 2: let's stay with the pharmaceutical space. What else do you have? Yeah,
Speaker 2: so I'm watching shares of psychedelic related companies, one of
Speaker 2: them Compas Pathways. The tickers CMPs shares are done by
Speaker 2: almost futy are up excuse me, by almost forty percent.
Speaker 2: It came after President Donald Trump signed an executive order
Speaker 2: to expedite research and access to different substances used outside
Speaker 2: the US to treat post traumatic stress disorder. So this
Speaker 2: applies to psychedelics with the so called breakthrough designation. So
Speaker 2: typically when a company does research trials, then at a
Speaker 2: lies for FDA for an approval. The typical process is
Speaker 2: about six to ten months. Now it's going to be
Speaker 2: one to two months. And analysts, of course see that
Speaker 2: as a big positive signal for those stocks. Okay, one more,
Speaker 2: what do you get? One more? Let's switch to AI space.
Speaker 2: I'm watching shares of for me. The ticker is FRMI.
Speaker 2: Shares are down by more than twenty percent today because
Speaker 2: we got news that CEO and CFO are stepping down.
Speaker 2: So FIRMI is a developer of nuclear power for data centers.
Speaker 2: It is building a massive data center capacity in Texas.
Speaker 2: It wants to power it with nuclear capacity, but there
Speaker 2: is a problem, so the company went to public last September.
Speaker 2: Since then, the stock dropped by more than seventy percent
Speaker 2: and the biggest concern for investors or analysts is that
Speaker 2: it still doesn't have enough tenants and as a result,
Speaker 2: it also lost one of the key anchor tenants, so
Speaker 2: lots of concerns.
Speaker 1: The stockmover's report from Bloomberg Radio. Check back with us
Speaker 1: throughout the day for the latest roundup of companies making
Speaker 1: news on Wall Street and for the latest market moving headlines.
Speaker 1: Listen to Bloomberg Radio Live, catch us on YouTube, Bloomberg
Speaker 1: dot com, and on Applecarplay and Android Auto with the
Speaker 1: Bloomberg Business app.